Abstract
Clostridioides difficile infection (CDI) is a major cause of nosocomial infection, leading to significant morbidity and mortality. While Faecal Microbiota Transplantation (FMT) is a promising option for recurrent and refractory CDI, the logistics of fresh stool preparation can be challenging. This study evaluates the safety, efficacy, and feasibility of using frozen stools from a newly established biobank in Hong Kong. In a retrospective review of 19 patients, frozen FMT achieved an 84.2% cure rate with an excellent safety profile, demonstrating its potential as a standard clinical intervention.
Introduction
Clostridioides difficile infection (CDI) represents a significant burden in healthcare settings, typically occurring after antibiotic use disrupts the natural balance of the gut microbiome. For patients with recurrent or refractory CDI, standard antibiotic treatments often fail, leading to chronic diarrhea, dehydration, and high mortality rates—particularly among elderly and frail populations.
Faecal Microbiota Transplantation (FMT) has emerged as a "gold standard" for restoring gut health by transferring stool from a healthy donor to a patient. However, using fresh stool is logistically difficult, requiring immediate processing and donor availability on short notice. To address these challenges, the Chinese University of Hong Kong (CUHK) established a stool biobank. This paper reviews the first major experience in Hong Kong using frozen stools for FMT in a quaternary referral centre.
Methods
The researchers conducted a retrospective, single-centre study of 19 consecutive patients treated for recurrent or refractory CDI using frozen stools from 2017 to the present.
Key Study Parameters: * Patient Cohort: 19 patients with a median age of 70 years (IQR 58.5–77.5). The group was medically fragile; nearly half were bedridden or chair-bound, and over 80% had recent hospitalizations or were residents of long-term care facilities. * Delivery Routes: FMT was administered via esophagogastroduodenoscopy (OGD) in 12 patients (63.2%), colonoscopy in 6 (31.6%), and feeding tube in 1 (5.3%). * Outcome Measures: The primary endpoint was the resolution of diarrhea without relapse within 8 weeks. Safety and clinical demographics were collected from the Hospital Authority’s Clinical Management System.
Results
The study yielded highly positive results, confirming the efficacy of frozen microbiota:
- Clinical Success: 16 out of 19 patients (84.2%) achieved full resolution of symptoms without relapse within the 8-week follow-up period.
- Safety Profile: The procedure was generally well-tolerated. No serious adverse events were attributable to the FMT itself.
- Minor Complications: Reported side effects were mild and transient, including abdominal pain (15.8%) and bloating (5.3%).
These results are consistent with international literature regarding fresh stool FMT, suggesting that the freezing process does not diminish the therapeutic potency of the donor microbiota.
Discussion
The transition from fresh to frozen stool is a significant logistical advancement for hospital workflows. It allows for rigorous, pre-emptive donor screening for pathogens (such as HIV, Hepatitis, and multi-drug resistant organisms), ensuring a safe, "off-the-shelf" treatment option is available when needed.
One of the most striking insights is the high efficacy (84.2%) maintained despite the poor functional status of the cohort. The successful use of the "upper route" (OGD) for the majority of patients also suggests that less invasive delivery methods are effective, which is particularly beneficial for elderly patients who may not tolerate a full colonoscopy.
Limitations and Future Directions
As a retrospective study with a small sample size (n=19), these findings serve as a proof-of-concept for the region. The reliance on existing medical records may also lead to the under-reporting of minor side effects compared to prospective trials. Future efforts should focus on raising clinician awareness to ensure FMT is used earlier in the treatment cycle for difficult-to-treat cases.
Conclusion
This study reports the largest case series of frozen stool FMT in Hong Kong, showing it to be a safe, efficacious, and logistically feasible intervention. The success of the CUHK stool biobank provides a model for expanding FMT access across other regions in Asia, potentially improving outcomes for high-risk CDI patients.
Reference: Lui R, et al. (2019). IDDF2019-ABS-0191 Initial experience of faecal microbiota transplantation with frozen stools for the treatment of recurrent or refractory clostridioides difficile infection. Gut, 68(Suppl 1):A100.
Summary updated